Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CAMBRIDGE NUTRITIONAL SCIENCES PLC Regulatory Filings 2021

Mar 26, 2021

7544_sha_2021-03-26_91234d3f-31eb-4989-b05f-2f8cfe53cb5c.html

Regulatory Filings

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 7102T

Omega Diagnostics Group PLC

26 March 2021

26 March 2021

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Exercise of Options and Total Voting Rights

Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that it has agreed to allot in total 14,673 new ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares"). This is following the exercise of share options under the Company's Sharesave scheme by Derek Brady, a PDMR of the Company, at a price of 18.4p per Ordinary Share. Following this exercise, Derek Brady holds 14,673 Ordinary Shares in the Company.

Application has been made to the London Stock Exchange for the 14,673 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 1 April 2021.

After Admission, the total number of Ordinary Shares in issue will be 182,269,796 and the total number of voting rights will therefore be 182,269,796. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.

Contacts: 

Omega Diagnostics Group PLC Tel: 01259 763 030
Colin King, Chief Executive www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director
finnCap Ltd Tel: 020 7220 0500
Geoff Nash / Teddy Whiley (Corporate Finance)
Alice Lane (ECM)
Walbrook PR Limited Tel: 020 7933 8780 or [email protected]
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person closely associated
a. Name Derek Brady
2 Reason for notification
a. Position/Status PDMR (Group Strategic Sourcing Director)
b. Initial notification/

Amendment
Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name Omega Diagnostics Group Plc
b. LEI 2138007U9P4BTZTYIR92
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument, type of instrument



Identification Code
Ordinary Shares of 4 pence each

ISIN: GB00B1VCP282
b. Nature of the transaction Acquisition of Ordinary Shares following the Exercise of Share Options
c. Price(s) and volume(s)
Price(s) Volume(s)
18.4p 14,673 Purchase
d. Aggregated information As above.
e. Date of the transaction 26 March 2021
f. Place of the transaction London Stock Exchange

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRSEIFWMEFSEDD